CRANEL After Shark Tank: Why $3.5 Million in Sales Didn’t Win a Deal

A cranberry shot is easy to demonstrate on television. A customer drinks it, reacts to the taste, and immediately understands how it fits into a routine. What viewers cannot see in that moment is whether people will keep buying it after the advertising stops, or whether the evidence behind cranberry products applies to that particular bottle.

Christine Jurzenski and Erica Schultz faced both questions when they brought CRANEL to Shark Tank. They reported millions of dollars in sales, yet the business was losing money while it paid to reach customers. They left without a deal. The brand still sells cranberry products, but the most useful part of the pitch is the gap between attracting a first-time buyer and building an economically sustainable habit.

Product snapshot

What is in the CRANEL pitch?

The founders describe CRANEL as a concentrated cranberry elixir taken once a week. Its small format gives it a different place in a shopping basket from a large bottle of cranberry juice. The brand advertises the equivalent of 3,000 cranberries in a shot. That is the manufacturer’s description of its concentrate; it is not a measure of how many infections a product prevents.

The FDA’s cranberry evidence review addresses specific daily amounts and formulations and a specific population: healthy women with a history of urinary tract infections. It describes qualified evidence, not an approval of CRANEL or a finding that a weekly shot treats an active infection. The distinction is particularly important here because the product schedule differs from the schedules in the FDA’s examples.

Who built CRANEL?

Jurzenski and Schultz tell their story in a first-person account of the broadcast. The photographs show the two presenting and the bottles lined up on set. The company’s store puts the elixir alongside other wellness products. For an emerging beverage business, a clearly defined ritual helps a shopper remember the product, but it also invites a test: after the novelty of the first pack, does the customer come back?

The product display from CRANEL’s account of the episode.

“No added sugar.” — CRANEL’s product description.

What happened to CRANEL on Shark Tank?

The founders asked for $250,000 for 7%, putting their proposed post-investment value at roughly $3.57 million. Episode reporting puts lifetime sales at about $3.5 million, with roughly $2 million in the previous year. The fact that two numbers are similar does not mean one validates the other: sales accumulate over time, while the asking valuation was a price for ownership on a particular day.

The more consequential number was a reported monthly loss of about $16,000. A second pitch account puts advertising spending in 2025 at $500,000 and describes Robert Herjavec’s concern about the marketing plan. No Shark invested. Unlike a business with untested consumer demand, CRANEL had evidence people would pay. The question was what it cost to persuade them to do so.

Deal snapshot

The critical sale is the second pack

A brand that buys advertising for the first purchase may earn back that cost through later purchases. The relevant comparison is not a four-pack’s shelf price against the cost of cranberry concentrate. It is the contribution from all the packs one customer buys, after packaging, delivery, promotions and other costs, against what it cost to acquire that customer.

That is why strong revenue and monthly losses can coexist. If customers reorder without another paid advertisement, the first pack can be an expensive introduction to a viable relationship. If most buyers try the shot once, paying for traffic starts the calculation over again. Neither public pitch account provides the customer retention data needed to settle the question.

Business model snapshot

What happened after Shark Tank?

Latest update — November 12, 2026. The CRANEL shop lists the One Stop Shot and other items. The brand also maintains its own account of the televised pitch.

Those pages support a current commercial presence and show how the company markets the drink. They do not independently verify health outcomes or establish that CRANEL became profitable after broadcast. The reported sales and spending figures belong to the period described in the pitch, and should stay attached to that period.

Current status evidence

Company timeline

What should a shopper compare?

Start with the label, serving schedule and total cost for the number of servings you want. A four-pack of weekly shots and a multi-serving bottle of juice are different purchases even if both feature cranberries. If health claims drive the decision, compare the product and schedule with the evidence being cited. A result for a daily cranberry preparation does not establish an equivalent result for a weekly concentrate.

Someone with symptoms of a possible urinary tract infection should seek medical advice rather than use a wellness shot as treatment. The FDA discussion concerns risk of recurrence in a defined population, not diagnosis or treatment of an infection.

What can founders learn from CRANEL?

CRANEL’s case gives founders a better question than “Did the campaign sell bottles?” Ask how many first-time buyers from that campaign return, how much those orders contribute, and when that contribution pays back the original advertising expense. Tracking those orders by acquisition month would make a stronger investment case than an impressive cumulative sales figure alone.

The Season 17 episode guide lists the other pitches. Readers following other consumer products with very different paths to repeat purchases can also find SOMNIA+, Screen Skinz, BocceRoll.

Frequently asked questions

Did CRANEL get a Shark Tank deal? No. None of the Sharks invested.

How much did the founders ask for? They offered 7% for $250,000.

Is CRANEL still selling products? Yes. Its storefront lists the cranberry shot.

Did it report $3.5 million in annual profit? No. That was reported lifetime sales, not annual profit.

Did the FDA approve this weekly shot to treat UTIs? No. The FDA review concerns qualified claims for specified cranberry products and reduced recurrence risk, not this weekly shot as treatment.